# US 2026/0083820 A1 · Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (ntsr1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083820 A1
- Document ID: US20260083820A1
- Status: Published application
- Kind: A1
- Application number: 19/349,587
- Filed: 2025-10-03
- Published: 2026-03-26
- Earliest claimed: 2022-11-28
- Assignees: New York Institute of Technology
- Applicants: New York Institute of Technology
- Inventors: Gonzalo Hugo OTAZU ALDANA
- Web page: https://patentgrep.com/patent/US20260083820A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and formulations for treating autism with neurotensin RI agonists without causing significant lethargy in a subject.

## Claims

### Claim 1

A formulation of a neurotensin R1 agonist for treating a symptom of an autism spectrum disorder without causing lethargy in a subject, comprising:
a) an amount of a neurotensin R1 agonist effective to treat a symptom of an autism; and
b) an amount of a polyethylene glycol polymer.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the neurotensin R1 agonist is a peptide neurotensin R1 agonist.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein duration of action of the neurotensin R1 agonist within a subject in the presence of the amount of a polyethylene glycol polymer is longer than duration of action of the same of amount of neurotensin R1 agonist in the presence of saline carrier in place of the polyethylene glycol polymer.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the neurotensin R1 agonist is a peptide neurotensin R1 agonist comprising the structure:

### Claim 5 (depends on 1)

The formulation of claim 1, encapsulated in a liposome.

### Claim 6 (depends on 1)

A product comprising a sub-cutaneous injector and the formulation of claim 1, as a liquid formulation.

### Claim 7

A method of treating a symptom of an autism spectrum disorder in a subject comprising administering to the subject an amount of a neurotensin R1 agonist effective to treat a symptom of an autism spectrum disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the symptom is a sensory symptom.

### Claim 9 (depends on 7)

The method of claim 7, wherein the neurotensin R1 agonist is a peptide neurotensin R1 agonist.

### Claim 10 (depends on 7)

The method of claim 7, wherein the amount of a neurotensin R1 peptide agonist is administered so as not to elicit drowsiness or so as not to elicit lethargy in the subject.

### Claim 11 (depends on 7)

The method of claim 7, wherein the amount of a neurotensin R1 peptide agonist is administered subcutaneously.

### Claim 12 (depends on 7)

The method of claim 7, wherein the subject has a SHANK3 haploinsufficiency or CNTNAP2 mutation.

### Claim 13 (depends on 12)

The method of claim 12, further comprising identifying the subject as having a SHANK3 haploinsufficiency or a CNTNAP2 mutation prior to administering the amount of a neurotensin R1 agonist.

### Claim 14 (depends on 8)

The method of claim 8, wherein the sensory symptom is an olfactory symptom.

### Claim 15 (depends on 7)

The method of claim 7, wherein the subject has not been diagnosed with schizophrenia or does not have schizophrenia.

### Claim 16 (depends on 7)

The method of claim 7, wherein the subject has not been diagnosed with stroke or has not suffered a stroke.

### Claim 17 (depends on 7)

The method of claim 7, wherein the subject is human.

### Claim 18 (depends on 7)

The method of claim 7, wherein the subject is male.

### Claim 19 (depends on 7)

The method of claim 7, wherein the subject is female.

### Claim 20 (depends on 7)

The method of claim 7, wherein neurotensin R1 agonist is administered as a formulation comprising:
a) an amount of a neurotensin R1 agonist effective to treat a symptom of an autism; and
b) an amount of a polyethylene glycol polymer.

### Claim 21 (depends on 7)

The method of claim 7, wherein the administered neurotensin R1 agonist is encapsulated in liposomes.
